Sanofi: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
Sanofi reported Q2 2026 net sales of €11,597m, up 17.8% at constant exchange rates, and business EPS of €2.09, up 33.3% at CER. Dupixent sales rose 37.6% to €5.2bn. Vaccines sales fell 4.7% to €1.1bn. Sanofi upgraded 2026 guidance to ~10% sales growth at CER and slightly faster business EPS growth, after completing a €1bn share buyback.
How this was made
The 30-second read
Why it matters
The key tradable catalyst is the explicit 2026 guidance upgrade to around 10% sales growth at CER with business EPS growing slightly faster than sales at CER, supported by Q2 outperformance and pipeline milestones.
Market read
Guidance upgrade plus strong Q2 business EPS growth and multiple regulatory milestones are likely to drive near-term repricing of 2026 earnings expectations.
What to watch
Pipeline decisions include discontinuing itepekimab and balinatunfib, and R&D and SG&A rose, which could pressure future margins if growth normalization does not materialize.
Background
Sanofi’s Q2 2026 update highlights double-digit sales growth at CER, business EPS strength, pipeline regulatory progress, and a completed €1 billion share buyback program.
Ticker impact
Sanofi reports Q2 2026 sales up 17.8% at CER, business EPS up 33.3% at CER, and upgrades 2026 guidance to ~10% sales growth at CER.
Likely positive near-term bias as guidance upgrade and EPS outperformance can re-rate expectations.
The article provides specific Q2 results and an explicit 2026 guidance upgrade, which are direct valuation drivers for a pharma large-cap.
Market effects
Positive read-through for large-cap pharma demand and pipeline execution, especially around Dupixent growth and multiple regulatory milestones.
Primarily impacts European pharma sentiment and cross-listed ADR positioning via SNY.
Could modestly influence global pharma peers’ sentiment around immunology and rare disease pipeline momentum.
Counterpoint
Vaccines sales declined 4.7% and IFRS net income fell sharply, so the quality of earnings may be more dependent on business metrics and one-offs than headline IFRS profitability.
Key entities
- companySanofi
Reports Q2 2026 sales and business EPS growth and upgrades 2026 guidance; also details pipeline approvals/readouts and capital allocation via a €1 billion buyback.
- productDupixent
Dupixent sales increased 37.6% to €5.2 billion, above €5 billion per quarter for the first time.
- productsAyvakit, ALTUVIIIO, Sarclisa
Pharma launches sales increased 48.3% to €1.3 billion, driven mostly by these products.
